• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

伴有产KPC菌血症的天然二尖瓣心内膜炎经二尖瓣置换术及头孢他啶-阿维巴坦成功治疗。

Native mitral valve endocarditis associated with KPC producing bacteremia successfully treated with mitral valve replacement and ceftazidime-avibactam.

作者信息

Tilanus Alwin, Rincon Francisco Mauricio, Rivera Aura Maria

机构信息

Internist-Infectious Disease Specialist, Department of Infectious Diseases, Clinica Los Nogales, Calle 95 # 23 - 61, Bogotá, Colombia.

Cardiovascular Surgeon, Department of Cardiovascular Surgery, Clinica Los Nogales, Calle 95 # 23 - 61, Bogotá, Colombia.

出版信息

IDCases. 2021 Apr 26;24:e01137. doi: 10.1016/j.idcr.2021.e01137. eCollection 2021.

DOI:10.1016/j.idcr.2021.e01137
PMID:33996466
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8105625/
Abstract

Consistent with global trends of infections due to multiple-drug resistant Gram-negative bacteria, we report the first official case of native mitral valve endocarditis due to multi-resistant Carbapenemase (KPC) producing . The patient underwent mitral valve replacement and was successfully treated with monotherapy ceftazidime-avibactam.

摘要

与耐多药革兰氏阴性菌感染的全球趋势一致，我们报告了首例由产多重耐药碳青霉烯酶（KPC）引起的原发性二尖瓣心内膜炎的官方病例。该患者接受了二尖瓣置换术，并成功接受了头孢他啶-阿维巴坦单药治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7781/8105625/3fb719e97d2f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7781/8105625/3fb719e97d2f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7781/8105625/3fb719e97d2f/gr1.jpg

相似文献

1
Native mitral valve endocarditis associated with KPC producing bacteremia successfully treated with mitral valve replacement and ceftazidime-avibactam.伴有产KPC菌血症的天然二尖瓣心内膜炎经二尖瓣置换术及头孢他啶-阿维巴坦成功治疗。
IDCases. 2021 Apr 26;24:e01137. doi: 10.1016/j.idcr.2021.e01137. eCollection 2021.
2
A challenging case of carbapenemase-producing Klebsiella pneumoniae septic thrombophlebitis and right mural endocarditis successfully treated with ceftazidime/avibactam.产碳青霉烯酶肺炎克雷伯菌脓毒性血栓性静脉炎和右心壁心内膜炎的治疗挑战：头孢他啶/阿维巴坦成功治疗
Infection. 2018 Oct;46(5):721-724. doi: 10.1007/s15010-018-1166-9. Epub 2018 Jun 20.
3
Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.头孢他啶-阿维巴坦治疗持续中性粒细胞减少兔产碳青霉烯酶肺炎克雷伯菌肺炎的药代动力学和疗效。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02157-19.
4
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
5
Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.产碳青霉烯酶肺炎克雷伯菌引起的对头孢他啶/阿维巴坦耐药的血流感染：流行病学与基因组特征。
Clin Microbiol Infect. 2020 Apr;26(4):516.e1-516.e4. doi: 10.1016/j.cmi.2019.11.011. Epub 2019 Nov 16.
6
Ceftazidime/avibactam susceptibility by three different susceptibility testing methods in carbapenemase-producing Gram-negative bacteria from Australia.三种不同药敏检测方法在澳大利亚产碳青霉烯酶革兰氏阴性菌中检测头孢他啶/阿维巴坦敏感性。
Int J Antimicrob Agents. 2018 Jul;52(1):82-85. doi: 10.1016/j.ijantimicag.2018.02.017. Epub 2018 Feb 27.
7
Ceftazidime/Avibactam for Refractory Bacteremia, Vertebral Diskitis/Osteomyelitis with Pre-Vertebral Abscess and Bilateral Psoas Pyomyositis Secondary to Klebsiella Pneumoniae Carbapenemase-Producing Bacteria (KPC).头孢他啶/阿维巴坦用于治疗由产肺炎克雷伯菌碳青霉烯酶（KPC）的细菌引起的难治性菌血症、伴有椎前脓肿的椎间盘炎/骨髓炎以及双侧腰大肌脓性肌炎。
P R Health Sci J. 2018 Jun;37(2):128-131.
8
Klebsiella pneumoniae carbapenemase (KPC) producer resistant to ceftazidime-avibactam due to a deletion in the blaKPC3 gene.产碳青霉烯酶肺炎克雷伯菌（KPC），由于 blaKPC3 基因缺失对头孢他啶-阿维巴坦耐药。
Clin Microbiol Infect. 2020 Jul;26(7):946.e1-946.e3. doi: 10.1016/j.cmi.2020.02.007. Epub 2020 Feb 12.
9
Serratia marcescens endocarditis treated with ceftazidime. A case report.用头孢他啶治疗粘质沙雷氏菌心内膜炎。病例报告。
S Afr Med J. 1983 Jul 16;64(3):105-6.
10
Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.2011年至2015年在美国医疗中心住院治疗肺炎的患者中分离出的革兰氏阴性菌对头孢他啶-阿维巴坦的抗菌活性
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02083-16. Print 2017 Apr.

本文引用的文献

1
Serratia marcescens Tricuspid Valve Vegetation and Successful Use of the AngioVac® System.粘质沙雷氏菌引起的三尖瓣赘生物及AngioVac®系统的成功应用
Cureus. 2020 Aug 25;12(8):e10010. doi: 10.7759/cureus.10010.
2
A Case of Endocarditis in a Nonintravenous Drug-Using Male Patient and Review of Literature.一名非静脉吸毒男性患者的心内膜炎病例及文献综述。
Case Rep Infect Dis. 2019 Jun 20;2019:3715404. doi: 10.1155/2019/3715404. eCollection 2019.
3
Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing .
头孢他啶-阿维巴坦单药及与厄他培南、磷霉素和替加环素联合治疗产碳青霉烯酶肠杆菌科细菌的活性
Microb Drug Resist. 2019 Nov;25(9):1357-1364. doi: 10.1089/mdr.2018.0234. Epub 2019 Jul 11.
4
A Complicated Case of Infective Endocarditis in the Era of the Current Opioid Epidemic.当前阿片类药物流行时代的一例复杂感染性心内膜炎病例
Case Rep Infect Dis. 2018 Nov 19;2018:5903589. doi: 10.1155/2018/5903589. eCollection 2018.
5
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
6
A challenging case of carbapenemase-producing Klebsiella pneumoniae septic thrombophlebitis and right mural endocarditis successfully treated with ceftazidime/avibactam.产碳青霉烯酶肺炎克雷伯菌脓毒性血栓性静脉炎和右心壁心内膜炎的治疗挑战：头孢他啶/阿维巴坦成功治疗
Infection. 2018 Oct;46(5):721-724. doi: 10.1007/s15010-018-1166-9. Epub 2018 Jun 20.
7
Ceftazidime/avibactam susceptibility by three different susceptibility testing methods in carbapenemase-producing Gram-negative bacteria from Australia.三种不同药敏检测方法在澳大利亚产碳青霉烯酶革兰氏阴性菌中检测头孢他啶/阿维巴坦敏感性。
Int J Antimicrob Agents. 2018 Jul;52(1):82-85. doi: 10.1016/j.ijantimicag.2018.02.017. Epub 2018 Feb 27.
8
Serratia infections: from military experiments to current practice.沙雷氏菌感染：从军事实验到当前实践。
Clin Microbiol Rev. 2011 Oct;24(4):755-91. doi: 10.1128/CMR.00017-11.
9
Serratia marcescens: historical perspective and clinical review.粘质沙雷氏菌：历史回顾与临床综述
N Engl J Med. 1979 Apr 19;300(16):887-93. doi: 10.1056/NEJM197904193001604.